Anthrax Vaccine Market by Vaccine Type, by Application, by End-User, and By Region

The global anthrax vaccine market size was estimated to be USD 13.02 billion in 2023 and is expected to reach USD 22.06 billion by 2034 with a CAGR of 4.91% during the forecast period 2024-2034. The rising bioterrorism threats and global security concerns, government initiatives and contracts, research and development advancements, global health concerns and natural outbreaks, and collaborations and partnerships will drive market growth.

The market for anthrax vaccination is mostly driven by government backing. The stability and expansion of the market are facilitated by government initiatives, contracts, and financing for R&D projects. Prolonged agreements with pharmaceutical firms offer certainty to vaccine producers, motivating them to persist in investing in manufacturing capacities. For instance, in November 2023, Pfizer Inc. and Valneva partnered to create a new anthrax vaccine utilizing Valneva's EB66 technology.

By vaccine type, the live attenuated vaccines segment accounted for the highest revenue-grossing segment in the global anthrax vaccine market in 2023 owing to the heightened demand for vaccines that provide long-lasting immunity, robust protection against anthrax, and the ability to stimulate a strong and sustained immune response. For instance, in December 2022, GSK and the University of Queensland worked together to develop a DNA plasmid-based next-generation anthrax vaccine candidate. Additionally, the cell-free PA vaccines segment is predicted to grow at the fastest CAGR during the forecast period owing to the advancements in biotechnology, particularly in recombinant DNA technology, which enables the production of highly purified and precisely engineered protective antigen (PA) subunits.

By application, the animal use segment accounted for the highest revenue-grossing segment in the global anthrax vaccine market in 2023 owing to the imperative need for safeguarding livestock populations against anthrax, particularly in regions with a history of anthrax outbreaks. For instance, Sanofi Pasteur's next-generation recombinant anthrax protein subunit vaccine candidate completed a Phase 2 clinical study in April 2023. Additionally, the human use segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of the importance of anthrax vaccination in safeguarding public health, particularly in regions where the risk of bioterrorism or natural anthrax outbreaks is a significant concern.

By end-user, the government stockpiles segment accounted for the highest revenue-grossing segment in the global anthrax vaccine market in 2023 owing to the strategic initiatives undertaken by governments worldwide to bolster their preparedness against potential bioterrorism threats and natural anthrax outbreaks. For instance, in June 2023, Bavarian Nordic A/S reported encouraging preclinical findings demonstrating a robust immune response in animal models for its single-dose anthrax vaccine candidate.Additionally, the clinics and veterinarians’ segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing emphasis on preventive veterinary care, rising awareness among pet owners about the importance of anthrax vaccination for animals, and the expanding role of veterinary clinics in promoting overall animal health.

North American region is anticipated to have the highest revenue share during the forecast period owing to the region's substantial investments in biodefense programs, robust healthcare infrastructure, and strategic initiatives aimed at enhancing preparedness against bioterrorism threats. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of the importance of biodefense measures, rising awareness about the potential threat of bioterrorism, and a growing focus on enhancing public health infrastructure. For instance, DynPort demonstrated effective and dependable manufacturing skills in March 2023 when they successfully finished a production run of their Anexsa anthrax vaccine for the US Department of Defense.

This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.

Report Scope:

• Base Year: 2023
• Forecast Period: 2024-2034
• Study Coverage
• Market Forecast by Vaccine Type, Application, and End-User
• Market Forecast for 5 Regions and 17+ Countries
• North America (U.S. and Canada)
• Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
• Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
• Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
• MEA (South Africa, GCC, Rest of MEA)
• Exhaustive Company Profiles of the Top 10+ Major Market Players
• 20% Free Customization Available to Meet Your Exact Requirement.

Segmentation: Anthrax Vaccine Market Report 2023 - 2034

Anthrax Vaccine Market Analysis & Forecast by Vaccine Type 2023 - 2034 (Revenue USD Bn)

• Cell-Free PA Vaccine
• Live Attenuated Vaccine

Anthrax Vaccine Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)

• Animal Use
• Human Use

Anthrax Vaccine Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)

• Hospitals
• Clinics and Veterinarians
• Government Stockpiles
• Others

Anthrax Vaccine Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• UK
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of LATAM
• Middle East & Africa
• South Africa
• GCC
• Rest of MEA